KRAS and Miyoshi myopathy: The landscape of neoantigens in 184 MM patients, as identified through next-generation sequencing, revealed shared neoantigens in NRAS, KRAS, and Interferon regulatory factor 4 (IRF4) genes in relapsed patients and in KRAS in newly diagnosed patients supporting the possibility of neoantigen-based vaccines in MM patients with such mutations (63).